Pfizer Updates Haleon Stake Filing

TL;DR

Pfizer filed an update on its Haleon stake - check the details.

AI Summary

Pfizer Inc. filed an amendment (No. 8) to its Schedule 13D on July 29, 2024, regarding its holdings in Haleon plc. The filing indicates changes in beneficial ownership of Haleon plc's ordinary shares and American Depositary Shares. Specific details on the exact percentage change or new ownership stake are not immediately clear from this header information but represent an update to their previous filing.

Why It Matters

This filing is important as it signals potential shifts in the ownership structure of Haleon plc, a significant player in the consumer healthcare market, which could impact its stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can indicate strategic shifts or market sentiment changes that could affect the company's stock.

Key Players & Entities

• Pfizer Inc. (company) — Filing entity
• Haleon plc (company) — Subject company

FAQ

From the Filing

0000078003-24-000153.txt : 20240729 0000078003-24-000153.hdr.sgml : 20240729 20240729163342 ACCESSION NUMBER: 0000078003-24-000153 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240729 DATE AS OF CHANGE: 20240729 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Haleon plc CENTRAL INDEX KEY: 0001900304 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-93722 FILM NUMBER: 241152893 BUSINESS ADDRESS: STREET 1: BUILDING 5, FIRST FLOOR STREET 2: THE HEIGHTS CITY: WEYBRIDGE STATE: X0 ZIP: KT13 0NY BUSINESS PHONE: 44 1932 822000 MAIL ADDRESS: STREET 1: BUILDING 5, FIRST FLOOR STREET 2: THE HEIGHTS CITY: WEYBRIDGE STATE: X0 ZIP: KT13 0NY FORMER COMPANY: FORMER CONFORMED NAME: DRVW 2022 Ltd DATE OF NAME CHANGE: 20211217 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 SC 13D/A 1 sch13da-july2024.htm SC 13D/A 8 HALEON PLC Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 66 Hudson Boulevard East New York, New York 10001-2192 (212) 733-2323 Copy to: Jacob A. Kling, Esq. Wachtell, Lipton, Rosen & Katz 51 West 52nd Street New York, New York 10019 (212) 403-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 29, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). **    This CUSIP applies to the Issuer’s American Depositary Shares, each representing two Ordinary Shares. No CUSIP has been assigned to the Ordinary Shares. 1 NAMES OF REPORTING PERSONS Pfizer Inc. (“ Pfizer ” or the “ Reporting Person ”) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INS